It's time to die: BH3 mimetics in solid tumors

被引:49
|
作者
Kehr, Sarah [1 ]
Vogler, Meike [1 ]
机构
[1] Goethe Univ Frankfurt, Inst Expt Canc Res Pediat, Komturstr 3a, D-60528 Frankfurt, Germany
来源
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH | 2021年 / 1868卷 / 05期
关键词
Apoptosis; Cancer; Bcl-2; Mcl-1; Bcl-xL; BH3; mimetics; BCL-X-L; MYELOID CELL LEUKEMIA-1; CHEMOTHERAPEUTIC-AGENTS; RHABDOMYOSARCOMA CELLS; FAMILY PROTEINS; SURVIVAL FACTOR; MITOTIC ARREST; MCL-1; LEADS; INHIBITOR; APOPTOSIS;
D O I
10.1016/j.bbamcr.2021.118987
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The removal of cells by apoptosis is an essential process regulating tissue homeostasis. Cancer cells acquire the ability to circumvent apoptosis and survive in an unphysiological tissue context. Thereby, the Bcl-2 protein family plays a key role in the initiation of apoptosis, and overexpression of the anti-apoptotic Bcl-2 proteins is one of the molecular mechanisms protecting cancer cells from apoptosis. Recently, small molecules targeting the anti-apoptotic Bcl-2 family proteins have been identified, and with venetoclax the first of these BH3 mimetics has been approved for the treatment of leukemia. In solid tumors the anti-apoptotic Bcl-2 family proteins Mcl-1 and Bcl-xL are frequently overexpressed or genetically amplified. In this review, we summarize the role of Mcl-1 and Bcl-xL in solid tumors and compare the different BH3 mimetics targeting Mcl-1 or Bcl-xL.
引用
收藏
页数:12
相关论文
共 50 条
  • [1] BH3 Mimetics in Hematologic Malignancies
    Klener, Pavel
    Sovilj, Dana
    Renesova, Nicol
    Andera, Ladislav
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (18)
  • [2] BH3 mimetics as a strategy to complement anticancer therapies
    Hartman, Mariusz L.
    Czyz, Malgorzata
    POSTEPY HIGIENY I MEDYCYNY DOSWIADCZALNEJ, 2012, 66 : 67 - 77
  • [3] Design of novel BH3 mimetics for the treatment of chronic lymphocytic leukemia
    Billard, C.
    LEUKEMIA, 2012, 26 (09) : 2032 - 2038
  • [4] Overview of BH3 mimetics in ovarian cancer
    Del Bufalo, Donatella
    Damia, Giovanna
    CANCER TREATMENT REVIEWS, 2024, 129
  • [5] BH3 Mimetics for the Treatment of B-Cell Malignancies-Insights and Lessons from the Clinic
    Lin, Victor S.
    Xu, Zhuo-Fan
    Huang, David C. S.
    Thijssen, Rachel
    CANCERS, 2020, 12 (11) : 1 - 24
  • [6] Sequential combinations of chemotherapeutic agents with BH3 mimetics to treat rhabdomyosarcoma and avoid resistance
    Alcon, Clara
    Manzano-Munoz, Albert
    Prada, Estela
    Mora, Jaume
    Soriano, Aroa
    Guillen, Gabriela
    Gallego, Soledad
    Roma, Josep
    Samitier, Josep
    Villanueva, Alberto
    Montero, Joan
    CELL DEATH & DISEASE, 2020, 11 (08)
  • [7] Sensitivity of canine hematological cancers to BH3 mimetics
    Jegatheeson, Selvi
    Cannon, Claire
    Mansfield, Caroline
    Devlin, Joanne
    Roberts, Andrew
    JOURNAL OF VETERINARY INTERNAL MEDICINE, 2023, 37 (01) : 236 - 246
  • [8] BH3 Mimetics for the Treatment of Prostate Cancer
    Wolf, Philipp
    FRONTIERS IN PHARMACOLOGY, 2017, 8
  • [9] Restoring Apoptosis with BH3 Mimetics in Mature B-Cell Malignancies
    Jullien, Maxime
    Gomez-Bougie, Patricia
    Chiron, David
    Touzeau, Cyrille
    CELLS, 2020, 9 (03)
  • [10] BH3 profiling discriminates on-target small molecule BH3 mimetics from putative mimetics
    Villalobos-Ortiz, Mariana
    Ryan, Jeremy
    Mashaka, Thelma N.
    Opferman, Joseph T.
    Letai, Anthony
    CELL DEATH AND DIFFERENTIATION, 2020, 27 (03) : 999 - 1007